Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.76 |
| ▸ | AKT1 | P31749 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509793 | 0.90 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| SCHEMBL28783397 | 0.89 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| SCHEMBL4517140 | 0.88 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| SCHEMBL924973 | 0.86 | PIK3CB (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| SCHEMBL4512724 | 0.84 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| SCHEMBL4527351 | 0.84 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| Trifluoroacetic Acid SCHEMBL926036 | 0.82 | PIK3CB (0.90) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| SCHEMBL17881201 | 0.79 | PIK3CD (0.85) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1619927 | 0.79 | AKT1 (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGAKT1 | |
| SCHEMBL926769 | 0.78 | PIK3CD (0.84) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101484452-A | Thiazole derivatives and their use as anti-tumour agents | ASTRAZENECA AB (SE) | 2009-07-15 | — | — | CN | disclosed |
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | MTOR, RPTOR, JAK2 | PIK3CD 31/4885PIK3CA 13/4885PIK3CB 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.